PriceTargets.com logo

Olink Holding AB (publ) - OLK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $26.00
  • Forecasted Upside: 18.88%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$21.87 As of 04/19/2024 01:00 AM ET
▼ -0.4 (-1.80%)

This chart shows the closing price for OLK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Olink Holding AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OLK

Analyst Price Target is $26.00
▲ +18.88% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Olink Holding AB (publ) in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 18.88% upside from the last price of $21.87.

This chart shows the closing price for OLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Olink Holding AB (publ). This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$26.00Low
3/26/2024Canaccord Genuity GroupReiterated RatingHold ➝ Hold$26.00Low
10/24/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$18.00 ➝ $26.00Low
10/18/2023ScotiabankReiterated RatingSector Outperform ➝ Sector PerformLow
10/17/2023Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
8/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$19.00 ➝ $18.00Low
2/22/2023Morgan StanleyBoost TargetEqual Weight$17.00 ➝ $18.00Low
2/22/2023The Goldman Sachs GroupBoost TargetNeutral$16.00 ➝ $18.00N/A
1/4/2023ScotiabankInitiated CoverageSector Outperform$27.00Low
12/14/2022Canaccord Genuity GroupInitiated CoverageBuy$28.00Low
11/15/2022SVB LeerinkBoost TargetOutperform$25.00 ➝ $27.00Low
11/11/2022Morgan StanleyBoost TargetEqual Weight$16.00 ➝ $17.00Low
8/12/2022Morgan StanleyBoost TargetEqual Weight$15.00 ➝ $16.00Low
7/14/2022The Goldman Sachs GroupLower TargetNeutral$20.00 ➝ $16.00Low
4/13/2022The Goldman Sachs GroupLower TargetNeutral$34.00 ➝ $20.00Medium
2/16/2022BTIG ResearchLower Target$44.00 ➝ $37.00High
2/14/2022Morgan StanleyLower TargetEqual Weight$33.00 ➝ $32.00High
11/11/2021SVB LeerinkLower TargetOutperform$50.00 ➝ $40.00High
8/12/2021Morgan StanleyLower TargetEqual Weight$38.00 ➝ $36.00High
6/6/2021SVB LeerinkReiterated RatingBuyMedium
5/21/2021Morgan StanleyLower TargetEqual Weight$40.00 ➝ $38.00High
4/19/2021SVB LeerinkInitiated CoverageOutperform$50.00High
4/19/2021Morgan StanleyInitiated CoverageEqual Weight$40.00High
4/19/2021The Goldman Sachs GroupInitiated CoverageNeutral$42.00High
4/19/2021BTIG ResearchInitiated CoverageBuy$44.00High
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Olink Holding AB (publ) logo
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Read More

Today's Range

Now: $21.87
Low: $21.80
High: $22.29

50 Day Range

MA: $23.38
Low: $21.81
High: $24.71

52 Week Range

Now: $21.87
Low: $14.10
High: $26.01

Volume

591,666 shs

Average Volume

386,384 shs

Market Capitalization

$2.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Olink Holding AB (publ)?

The following Wall Street sell-side analysts have issued stock ratings on Olink Holding AB (publ) in the last year: Canaccord Genuity Group Inc., Leerink Partnrs, Morgan Stanley, and Scotiabank.
View the latest analyst ratings for OLK.

What is the current price target for Olink Holding AB (publ)?

2 Wall Street analysts have set twelve-month price targets for Olink Holding AB (publ) in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 18.9%. Morgan Stanley has the highest price target set, predicting OLK will reach $26.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $26.00 for Olink Holding AB (publ) in the next year.
View the latest price targets for OLK.

What is the current consensus analyst rating for Olink Holding AB (publ)?

Olink Holding AB (publ) currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OLK, but not buy more shares or sell existing shares.
View the latest ratings for OLK.

What other companies compete with Olink Holding AB (publ)?

Other companies that are similar to Olink Holding AB (publ) include 10x Genomics, GenMark Diagnostics, Luminex, Meridian Bioscience and Lantheus. Learn More about companies similar to Olink Holding AB (publ).

How do I contact Olink Holding AB (publ)'s investor relations team?

Olink Holding AB (publ)'s physical mailing address is UPPSALA SCIENCE PARK, UPPSALA V7, 75183. The company's listed phone number is 46 (0) 18 444 39 70 and its investor relations email address is [email protected]. The official website for Olink Holding AB (publ) is www.olink.com. Learn More about contacing Olink Holding AB (publ) investor relations.